Recoflavone

Summary

Recoflavone (CHEMBL4297606) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including chronic gastritis and gastritis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 3
• Chemistry: 386.4 Da · C20H18O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297606
Name	Recoflavone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9952125
Molecular formula	C20H18O8
Molecular weight	386.4
InChIKey	BCPQOBQIVJZOFL-UHFFFAOYSA-N

SMILES: COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3OC)OCC(=O)O)OC

IUPAC name: 2-[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxochromen-7-yl]oxyacetic acid

Also known as: DA 6034, Da-6034, DA-6034, Recoflavona, Recoflavone, RECOFLAVONE

Patent coverage: 29 distinct patent families (117 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 70 (60%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic gastritis	3	MONDO:0005001	EFO:0000337
gastritis	3	MONDO:0004966	EFO:0000217
dry eye syndrome	2	MONDO:0006733	EFO:1000906

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01813812	PHASE3	UNKNOWN	A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034
NCT01670357	PHASE2	COMPLETED	Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome
NCT01162954	PHASE1	COMPLETED	Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).